OPKO Health, Inc. Stock News

MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 at the Lotte New York Palace Hotel in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Wednesday, Dece...

OPKO Health, Inc. ( OPK ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Phillip Frost - Chairman & CEO Elias Zerhouni - President & Vice Chairman Adam Logal - Senior VP & CFO Gary Nabel - Chief Information Officer & Director Conference Call Participants Yvonne Briggs - LHA Investor Relations Maurice Raycroft - Jefferies LLC, Research Division Yi Chen - H.C. Wainwright ...

MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies.

MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, October 29, 2025. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live aud...

BURLINGTON, N.C. and MIAMI , Sept.

Opko Health (OPK) Q2 Revenue Falls 14%

OPKO Health, Inc. (NASDAQ:OPK ) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Adam E. Logal - Senior VP & CFO Elias Adam Zerhouni - President & Vice Chairman Phillip Frost - Chairman & CEO Yvonne Briggs - LHA Investor Relations Conference Call Participants Edward Andrew Tenthoff - Piper Sandler & Co., Research Division I-Eh Jen - Laidlaw & Company (UK) Ltd.

MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include the following: Merck advanced Phase 1 Epstein-Barr virus vaccine trial ( NCT06655324 ).